1型糖尿病,COVID-19疫苗和短期安全性:来自全球COVAD研究的子组分析
Tulika Chatterjee1, Naveen Ravichandran2, Narmadha Nair3
1Department of Internal Medicine, Center for Outcomes Research, University of Illinois College of Medicine Peoria, Peoria, Illinois, USA.
Journal of diabetes investigation
|September 12, 2023
概括
对于1型糖尿病患者来说,COVID-19疫苗接种是安全的,与健康个体相似的不良事件. 在接受COVID-19疫苗的1型糖尿病患者中,严重的皮疹更常见,但很少见.
科学领域:
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
- 公共卫生 公共卫生
背景情况:
- 在健康人群中,COVID-19疫苗通常是安全的.
- 关于1型糖尿病患者疫苗安全性的数据有限.
- 了解1型糖尿病的不良事件对于公共卫生战略至关重要.
研究的目的:
- 在1型糖尿病患者接种COVID-19疫苗后,评估短期不良疫苗接种事件 (<7天) 的频率和严重程度.
- 为了比较1型糖尿病患者和健康对照者之间的不良事件概况.
- 确定1型糖尿病患者不良事件的危险因素.
主要方法:
- 在自身免疫性疾病 (COVAD) 调查中分析了COVID-19疫苗接种数据.
- 1型糖尿病患者和健康对照者之间的不良事件的比较.
- 使用了描述性统计和多变量分析.
主要成果:
- 1型糖尿病患者的注射部位疼痛,轻微/重大不良事件和住院住院的风险与健康对照者相比相当.
- 在1型糖尿病患者中观察到较高的严重皮疹风险 (3%vs0.4%),尽管这些事件很少发生.
- 瑞疫苗是最常见的疫苗,大多数参与者接受了两剂.
结论:
- 接种COVID-19疫苗是安全的,并且在1型糖尿病患者中耐受良好.
- 整体不良事件的概况与一般人群的概况相似.
- 虽然严重的皮疹在1型糖尿病患者中更常见,但它们仍然不常见.
相关概念视频
Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Insulin: Dosing Regimen and Adverse Effects
205
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
205
Diabetes: Management and Pharmacotherapy
309
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
309
Diabetes: Symptoms, Diagnosis, and Complications
581
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
581
Hypoglycemia and Glucagon
294
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
294


